{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:19Z","timestamp":1792597099508,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cll.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:13:38Z","timestamp":1786493618000},"page":"785-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Drug\u2019s the Same but the Range Has Changed"],"prefix":"10.1016","volume":"46","author":[{"given":"Nicholas E.","family":"Heger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.H.","family":"Snozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to determine a therapeutic reference range for a psychotropic drug systematically? Recommendations of the TDM task force of the AGNP","volume":"47","author":"Hart","year":"2025","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/dx-2018-0001","article-title":"Quality, origins and limitations of common therapeutic drug reference intervals","volume":"5","author":"McCudden","year":"2018","journal-title":"Diagnosis (Berl)"},{"issue":"8","key":"10.1016\/j.cll.2026.07.009_bib3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cmi.2020.03.008","article-title":"How to design a study to evaluate therapeutic drug monitoring in infectious diseases?","volume":"26","author":"Martson","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.cll.2026.07.009_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.cll.2026.07.009_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/epi.18330","article-title":"Evaluation of antiseizure medication concentration ranges in blood samples using an automated big data approach","volume":"66","author":"Nersesjan","year":"2025","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.cll.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.9740\/mhc.2019.07.287","article-title":"A review of a recently published guidelines\u2019 \u201cstrong recommendation\u201d for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine","volume":"9","author":"Noel","year":"2019","journal-title":"Ment Health Clin"},{"issue":"6","key":"10.1016\/j.cll.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/14737175.8.6.929","article-title":"Value of therapeutic drug monitoring in epilepsy","volume":"8","author":"Johannessen","year":"2008","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.cll.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.cll.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0960327112446516","article-title":"The effect of combination therapy on the plasma concentrations of traditional antiepileptics: a retrospective study","volume":"31","author":"Sirmagul","year":"2012","journal-title":"Hum Exp Toxicol"},{"issue":"9","key":"10.1016\/j.cll.2026.07.009_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26094035","article-title":"Antiepileptic drug combinations for epilepsy: mechanisms, clinical strategies, and future prospects","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cll.2026.07.009_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.760181","article-title":"The more, the merrier.? Antipsychotic polypharmacy treatment strategies in schizophrenia from a pharmacology perspective","volume":"12","author":"Hjorth","year":"2021","journal-title":"Front Psychiatry"},{"issue":"3 Epilepsy","key":"10.1016\/j.cll.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.CON.0000368236.41986.24","article-title":"Antiepileptic drugs: adverse effects and drug interactions","volume":"16","author":"Tatum","year":"2010","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020673","article-title":"Automated interlaboratory comparison of therapeutic drug monitoring data and its use for evaluation of published therapeutic reference ranges","volume":"15","author":"Larsen","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib14","first-page":"153","article-title":"Age-stratified lithium therapeutic ranges for older adults with bipolar disorder - from awareness to an action plan","volume":"34","author":"Fung","year":"2023","journal-title":"EJIFCC"},{"issue":"9","key":"10.1016\/j.cll.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clinbiochem.2015.03.009","article-title":"How appropriate is therapeutic drug monitoring for lithium? Data from the Belgian external quality assessment scheme","volume":"48","author":"Delattre","year":"2015","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.cll.2026.07.009_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/FTD.0000000000000043","article-title":"Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring","volume":"36","author":"Shipkova","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cll.2026.07.009_bib17","series-title":"Therapeutic drugs and their management. Tietz textbook of laboratory medicine","first-page":"420","author":"Milone","year":"2023"},{"issue":"1","key":"10.1016\/j.cll.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40345-024-00362-7","article-title":"Lithium: current state of the art and future directions","volume":"12","author":"Gitlin","year":"2024","journal-title":"Int J Bipolar Disord"},{"key":"10.1016\/j.cll.2026.07.009_bib19","series-title":"C-B 2025 participant summary (PS)","author":"CAP","year":"2025"},{"key":"10.1016\/j.cll.2026.07.009_bib20","series-title":"Digoxin","author":"David","year":"2024"},{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70083","article-title":"New monitoring recommendations for digoxin during the last decade are associated with decreased serum digoxin concentrations in patient samples","volume":"137","author":"Larsson","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"10.1016\/j.cll.2026.07.009_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1592\/phco.19.15.1123.30570","article-title":"Therapeutic range of digoxin\u2019s efficacy in heart failure: what is the evidence?","volume":"19","author":"Terra","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.cll.2026.07.009_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cll.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.amjcard.2012.02.028","article-title":"Therapeutic ranges of serum digoxin concentrations in patients with heart failure","volume":"109","author":"Goldberger","year":"2012","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.cll.2026.07.009_bib25","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of Cardiology\/American heart Association Joint Committee on clinical practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.009_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of Cardiology\/American Heart Association Joint Committee on clinical practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cll.2026.07.009_bib27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jacc.2017.12.060","article-title":"Digoxin and mortality in patients with atrial fibrillation","volume":"71","author":"Lopes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cll.2026.07.009_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1179892","article-title":"Review: failure of current digoxin monitoring for toxicity: new monitoring recommendations to maintain therapeutic levels for efficacy","volume":"10","author":"Gona","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"13\u201314","key":"10.1016\/j.cll.2026.07.009_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.clinbiochem.2015.06.010","article-title":"Multi-center evaluation of analytical performance of the beckman coulter AU5822 chemistry analyzer","volume":"48","author":"Zimmerman","year":"2015","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.cll.2026.07.009_bib30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pro.3819","article-title":"Molecular mechanisms of vancomycin resistance","volume":"29","author":"Stogios","year":"2020","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.cll.2026.07.009_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/psp4.13253","article-title":"Vancomycin population pharmacokinetic models: uncovering pharmacodynamic divergence amid clinicobiological resemblance","volume":"14","author":"Gandia","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2026.07.009_bib32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cll.2026.07.009_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cll.2026.07.009_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jad.2017.03.052","article-title":"The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines","volume":"217","author":"Malhi","year":"2017","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.cll.2026.07.009_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bdi.12805","article-title":"What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD\/IGSLI task force on treatment with lithium","volume":"21","author":"Nolen","year":"2019","journal-title":"Bipolar Disord"},{"issue":"2","key":"10.1016\/j.cll.2026.07.009_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bdi.12714","article-title":"Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report","volume":"21","author":"Shulman","year":"2019","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.cll.2026.07.009_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2025.111057","article-title":"Analytical imprecision and therapeutic intervals for lithium - are there implications for old age patients with bipolar disorder?","volume":"141","author":"Zhou","year":"2026","journal-title":"Clin Biochem"},{"issue":"5","key":"10.1016\/j.cll.2026.07.009_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1\u201302","key":"10.1016\/j.cll.2026.07.009_bib39","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cll.2026.07.009_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.cll.2026.07.009_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70353","article-title":"A comparison of AI and population PK models to predict the concentrations of antiepileptic drugs using therapeutic drug monitoring records","volume":"18","author":"Chung","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"36","key":"10.1016\/j.cll.2026.07.009_bib42","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cll.2026.07.009_bib56","series-title":"Disposition of toxic drugs and chemicals in man","author":"Baselt","year":"2020"},{"issue":"5","key":"10.1016\/j.cll.2026.07.009_bib57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry","volume":"44","author":"Warner","year":"1998","journal-title":"Clin Chem"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227122600079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227122600079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:37Z","timestamp":1792593637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027227122600079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S027227122600079X"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.009","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Drug\u2019s the Same but the Range Has Changed","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}